Close menu

– Drug candidate ABD-3001 is a galenic form of DIMATE, a first-in-class suicide inhibitor of aldehyde dehydrogenase 1 (ALDH1), being tested in relapsed patients with limited therapeutic options.


– Preliminary data from the First-in-human ODYSSEY study show that ABD-3001 was well tolerated, with activity of the drug candidate on its target, as well as proven biological activity, observed at all doses tested.


– Preliminary signs of efficacy were observed in over 65% of patients treated, two of whom benefited from a long-term treatment effect.


– These results pave the way for the second phase of the ODYSSEY trial, during which three cohorts of patients are scheduled to receive full three-month treatment cycles, enabling initial efficacy results to be obtained.


Lyon (France), June 4, 2024 – Advanced BioDesign, a biotech company specializing in the development of new therapeutic approaches to resistant cancers, has released the first data from its first-in-human ODYSSEY study, aimed at treating acute myeloid leukemia (AML) with the drug candidate ABD-3001.


“We are delighted to have demonstrated the good safety and tolerability of our drug candidate ABD- 3001 in this Phase I/II trial in AML patients resistant to standard therapies. The objectives of this first part of the study were met, and even exceeded our expectations. Not only did we observe activity of our drug candidate on its target of interest, ALDH1, but we also observed biological activity at all the doses tested. These results are very encouraging and allow us to enthusiastically begin the second phase of this study, during which several treatment cycles will be evaluated at optimized dose regimens to confirm ABD-3001’s position in the therapeutic arsenal for the treatment of acute myeloid leukemia. I would like to thank all our patients and investigators for their involvement”, said Ismail Ceylan, CEO of Advanced BioDesign.



Read the press release

More information